Curis (NASDAQ:CRIS) Shares Cross Above 200 Day Moving Average of $10.73

Curis, Inc. (NASDAQ:CRIS)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.73 and traded as high as $15.27. Curis shares last traded at $15.27, with a volume of 22,370 shares.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price target on shares of Curis from $51.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, February 9th.

Curis Trading Down 4.6 %

The stock’s 50 day moving average price is $11.51 and its two-hundred day moving average price is $9.95. The firm has a market capitalization of $89.65 million, a price-to-earnings ratio of -1.63 and a beta of 3.72.

Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, February 8th. The biotechnology company reported ($2.03) earnings per share for the quarter, missing the consensus estimate of ($1.91) by ($0.12). The business had revenue of $2.70 million for the quarter, compared to analysts’ expectations of $2.95 million. Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. During the same quarter last year, the business posted ($2.40) earnings per share. On average, sell-side analysts forecast that Curis, Inc. will post -5.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CRIS. HRT Financial LP bought a new stake in Curis in the fourth quarter valued at $29,000. Engineers Gate Manager LP bought a new position in shares of Curis in the first quarter valued at $32,000. UBS Group AG raised its position in shares of Curis by 183.6% during the third quarter. UBS Group AG now owns 51,332 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 33,231 shares during the period. Virtu Financial LLC acquired a new stake in Curis during the 4th quarter worth about $51,000. Finally, Bank of Montreal Can purchased a new stake in shares of Curis in the 2nd quarter valued at approximately $59,000. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.